NEW YORK, Nov. 20 - Decode today said Wyeth will use its gene-expression data to study treatments for an undisclosed respiratory disease.
Terms of the collaboration call for Decode's clinical trials subsidiary, Encode, to generate in vitro gene-expression profiles of peripheral mononuclear cells isolated from patients exposed to Wyeth's drug.
No other information was provided.